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Background: Our previous laboratory and clinical data suggested that one mechanism underlying the development of platinum resistance in
ovarian cancer is the acquisition of DNA methylation. We therefore tested the hypothesis that the DNA hypomethylating agent 5-aza-20-
deoxycytodine (decitabine) can reverse resistance to carboplatin in women with relapsed ovarian cancer.
Methods: Patients progressing 6–12 months after previous platinum therapy were randomised to decitabine on day 1 and carboplatin (AUC 6) on
day 8, every 28 days or carboplatin alone. The primary objective was response rate in patients with methylated hMLH1 tumour DNA in plasma.
Results: After a pre-defined interim analysis, the study closed due to lack of efficacy and poor treatment deliverability in 15 patients treated with
the combination. Responses by GCIG criteria were 9 out of 14 vs 3 out of 15 and by RECIST were 6 out of 13 vs 1 out of 12 for carboplatin and
carboplatin/decitabine, respectively. Grade 3/4 neutropenia was more common with the combination (60% vs 15.4%) as was G2/3 carboplatin
hypersensitivity (47% vs 21%).
Conclusions: With this schedule, the addition of decitabine appears to reduce rather than increase the efficacy of carboplatin in partially
platinum-sensitive ovarian cancer and is difficult to deliver. Patient-selection strategies, different schedules and other demethylating agents should
be considered in future combination studies.
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Ovarian cancer accounted for an estimated 140 000 deaths
worldwide in 2008 (Ferlay et al, 2010). Most women present with
advanced disease, and although initially chemosensitive, the
majority of tumours recur with ultimate failure of conventional
cytotoxic drugs. Thus acquired resistance represents a major
clinical challenge, and an understanding of the mechanisms
involved may offer the opportunity for therapeutic intervention.
Alteration of the epigenetic state of tumour cells offers one
mechanism by which resistance may develop (Glasspool et al,
2006). Aberrant methylation and associated transcriptional silen-
cing of genes is frequently seen in ovarian tumours and is seen
more often in cells that acquire drug resistance following chronic
exposure to cisplatin (Dai et al, 2008; Chang et al, 2010).
Methylation of a subset of genes is associated with short
progression-free survival (PFS) following chemotherapy (Wei
et al, 2006). However, promoter methylation of certain genes has
also been implicated in sensitivity to chemotherapy (Zeller and
Brown 2010), suggesting that it may be necessary to identify
specific methylation profiles that are associated with drug
resistance and sensitivity.
A relatively small number of genes that are potential drivers of
platinum resistance (Zeller et al, 2012) have been identified by
combined expression and methylation profiling following treat-
ment of ovarian cell line models with the demethylating agent
5-aza-20-deoxycitidine (decitabine). One of these key loci is MLH1
where DNA methylation and resulting loss of expression of this
DNA mismatch repair gene may decrease response to chemother-
apy (Brown et al, 1997). In drug-resistant xenograft tumour models
with methylated MLH1, the methyltransferase (DNMT) inhibitor,
decitabine, induces re-expression of MLH1 and sensitises the drug-
resistant tumour xenografts to carboplatin (Plumb et al, 2000). In
vivo, methylation and loss of MLH1 expression occur at higher
frequency in post chemotherapy compared with pre-chemotherapy
samples (Strathdee et al, 1999). Methylation of MLH1 is increased
in plasma DNA samples of patients with EOC at relapse following
first-line carboplatin/taxane chemotherapy compared with
matched pre-chemotherapy samples. Furthermore, acquisition of
MLH1 methylation in plasma DNA at relapse is an independent
predictor of poor overall survival (OS; Gifford et al, 2004). Thus we
hypothesised that acquired methylation and associated gene
silencing, particularly of the MLH1 promoter, during chemother-
apy contributes to acquired platinum resistance in EOC and that
this could be reversed by decitabine.
A phase I study demonstrated the feasibility of a 4 weekly
schedule where decitabine 90mgm 2 was given on day 1 and
carboplatin (AUC 6) on day 8, to allow time for demethylation and
re-expression of methylated genes before administration of
carboplatin (Appleton et al, 2007). Here we describe a randomised
phase II trial using this dose and schedule vs carboplatin alone in
women with EOC, relapsing 6–12 months after previous platinum-
based chemotherapy.
PATIENTS AND METHODS
Study design. This was a multicentre, open label, randomised
phase II study, sponsored by Cancer Research UK. The study was
conducted according to the principles of good clinical practice and
in accordance with the Declaration of Helsinki and approved by an
ethical review committee. Patients gave written informed consent.
The primary objective was to estimate response rate (RR) by GCIG
criteria (Rustin et al, 2011) in patients with methylated hMLH1
CGI DNA in plasma. Secondary objectives were: RR regardless of
methylation status; PFS and OS; safety and tolerability; feasibility;
incidence of hypersensitivity reactions; and the relationship
between peak plasma levels of decitabine and global or CpG
island-specific methylation. The primary end point was defined as
any response (PR or CR) in patients with methylated hMLH1 CGI
DNA in plasma as determined by RECIST criteria or, in patients
without measurable disease, by CA-125 levels. The best overall
response combining CA-125 and RECIST was determined using
the GCIG guidelines from November 2005 (Rustin et al, 2011). The
secondary end points were defined as follows. Overall RR was any
response (PR or CR) in any of the patients as determined by
RECIST criteria or in patients without measurable disease by
CA-125 levels. The best overall response combining CA-125 and
RECIST was determined using the GCIG guidelines from
November 2005. PFS was defined as the time from randomisation
to progression or death from any cause (whichever occurs first).
Patients who did not experience either of these events were
censored at the last date of follow-up. OS was defined as time from
randomisation to death from any cause. Patients who did not
experience either of these events were censored at the last date of
follow-up. Causality of each adverse event to decitabine and/or
carboplatin and grade severity was defined according to CTCAE
Version 3.0. Further end points were the total dose and dose
intensity of carboplatin and decitabine received, the incidence of
grade 3 and 4 hypersensitivity reactions, the plasma levels of
decitabine 1 h after the start of the decitabine infusion in the
combination arm and global levels and CpG island-specific DNA
methylation in peripheral mononuclear cells.
Eligibility. Eligibility criteria were as follows: EOC, fallopian tube
cancer or primary peritoneal cancer; age418 years; a maximum of
two previous lines of treatment: a platinum regimen as their most
recent treatment; initial response by RECIST and/or CA-125
criteria but relapse 6-12 months after last platinum treatment;
measurable disease by RECIST and/or by GCIG CA-125 criteria;
PS (WHO) 0-2; and haematological and biochemical indices within
standard ranges. Patients were excluded if considered intolerant to
carboplatin AUC 5 due to excessive myelotoxicity or hypersensi-
tivity reaction.
Treatment plan. Women were randomised between: (A) Carbo-
platin (AUC 6 based on GFR measured by radioisotope assay)
intravenously on d1 every 28 days or (B) decitabine (90mgm 2
and subsequently 45mgm 2) as a 6-h IV infusion on d1 and
Carboplatin (AUC 6) on d8 every 28 days.
If the re-treatment criteria were not met on d1 (Arm A or
Arm B) or on d8 (Arm B), treatment was delayed. If the delay was
p7 days, the doses were maintained, but if between 8 and 15 days
the dose was reduced by one dose level. If re-treatment criteria
were not met after 15 days, the patient was removed from the
study. If patients experienced grade 4 neutropenia complicated by
feverX38.5 1C; or lastingX7 days; thrombocytopeniap25 109 l 1;
or any grade 3 or 4 non-haematological AE, the dose was reduced
by one level. Dose levels were Arm A: level  1 AUC 5 carboplatin,
level  2 remove from study; Arm B: dose level  1 decitabine
45mgm 2, level  2 carboplatin AUC 5, level  3 stop decitabine
and continue carboplatin alone. Prophylactic use of growth factors
was not permitted.
Statistical methods. Patients were randomised 1 : 1 between the
study arms, using a minimisation algorithm incorporating a
random component (Scott et al, 2002). Stratification factors were
first-line treatment received, number of previous lines of treatment,
WHO PS and assessable disease criteria.
The planned recruitment was 134 patients, which was estimated
to allow inclusion of approximately 40 patients with methylated
MLH1 DNA in plasma assuming a methylation rate of 30%
(derived from our previous study of patients relapsing after first-
line therapy (Gifford et al, 2004)). This would enable a difference
in RR between the two arms to be estimated with a s.e. of 12% and
give an 85% probability that the response difference favoured the
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combination arm, assuming RR of 10% and 25%, respectively, on
the carboplatin and combination arms in women with methylated
MLH1 DNA in plasma. With the total sample of 134, the difference
in overall RR between the two arms could be estimated with a s.e.
of 8% and give an 96% probability that the response difference in
the overall population favoured the combination assuming a RR in
the carboplatin alone group of 25% rising to 40% in the
combination arm. There was an early stopping rule if no responses
were seen in the first 11 patients in the combination arm. The
probability of stopping at this point was o5% if the true RR was
425%. As the study was closed early because of observed poor
response and tolerability of the combination arm, the P-values for
comparison of the end points between the arms will be more
extreme than they would be for a non-data-prompted analysis.
The Kruskal-Wallis test was used to compare neutropenia
grades and relative carboplatin dose intensity. Spearman’s rank
correlation was used to examine the associations between day 1
decitabine concentration and minimum global methylation and
area above the methylation curve. Kaplan-Meier techniques were
used to estimate PFS.
Collection of pharmacokinetic and pharmacodynamic samples.
Assays integral to the primary or secondary objectives of the trial
were conducted using validated standard operating procedures.
Assays were performed as previously described (Gifford et al, 2004;
Appleton et al, 2007).
RESULTS
Patients. Twenty-nine patients had entered the study when the
first efficacy analysis was performed. The first four patients in Arm
B at 90mgm 2 decitabine (B90) all required a dose delay of 1–2
weeks before cycle 2, and three required a dose reduction of
decitabine. In contrast, only one of the five patients in Arm A
(carboplatin alone) recruited during the same time period required
a delay of 1 week with no dose reductions. The starting dose of
decitabine was therefore reduced to 45mgm 2 for subsequent
patients (B45). Allowing for the relatively small numbers in the
groups, there was no marked imbalance between the arms
(Table 1).
Feasibility. In Arm A, 8 of the 14 patients completed six or more
cycles. In contrast, no patients in Arm B received six cycles of
decitabine and carboplatin. The reasons for stopping assigned
treatment are shown in Table 2.
Dose delays and reductions. Dose delays due to clinical reasons
are shown in Table 2. The most common cause of dose delay
overall was neutropenia (two patients (three episodes) in A, four
patients (six episodes) in B90 and four patients (four episodes) in
B45). Delay in starting cycle 2 due to neutropenia was more
common in the combination arm with one patient in Arm A, four
in B90 and four in B45. The dose of decitabine was reduced in
three patients on B90. In B45, three patients stopped decitabine
due to toxicity, continuing with carboplatin alone. Reductions in
carboplatin were similar across arms.
Adverse events. The most noteworthy adverse events were
hypersensitivity and neutropenia. Grade 3/4 neutropenia was seen
in 100%, 45.5% and 15.4% on B90, B45 and A respectively. The
difference in nadir neutropenia was statistically significant across
all arms but not between Arm A and B45 (P¼ 0.008 and P¼ 0.172,
respectively), indicating that the difference was mainly due to B90
patients. Ten patients in the combination experienced hypersensi-
tivity reactions (17 episodes) compared with 3 patients in Arm A
(6 episodes). Although patients were given a desensitising regime
Table 1. Patient characteristics
Arm A,
n¼14
Arm
B90,
n¼4
Arm
B45,
n¼11
Mean age (years) 57.7 60 59.5
Median time from last platinum treatment to
first/second relapse (months)
8.05 7.12 8.02
Type of first-line chemotherapy (%)
Platinum alone 21.4 0 27.3
Platinum plus taxane 78.6 75 72.7
Platinum plus other 0 25 0
Response to most recent treatment (%)
Complete response 50 50 18.2
Partial response 42.9 50 45.5
Stable disease 0 0 18.2
Adjuvant 7.1 0 18.2
Number of lines of previous treatment
1 92.9 75 90.9
2 7.1 25 9.1
Table 2. Number of cycles of assigned chemotherapy completed, reason
for stopping assigned treatment before six cycles, dose delays and dose
reductions by treatment arm
Arm A,
n¼14
Arm B90,
n¼4
Arm B45,
n¼11
Total number of cycles received (as per protocol)
1 cycle 3 0 3a
2 cycles 0 3b 3
3 cycles 0 0 0
4 cycles 2 1c 3c
5 cycles 1 0 2
6 cycles 7 0 0
7 cycles 1 0 0
Reason for stopping assigned treatment before six cycles
Progressive disease 3 2 3
Neutropenia 2 2 2
Neutropenia and
Thrombocytopenia
0 1
Hypersensitivity to carboplatin 1 1 3
Nausea and fatigue 0 0 1
Decitabine withdrawn when
study terminated early
0 0 1
Number of patients with clinical dose delays lastingX7 days
Cycle at which delay occurred Arm A Arm B90 Arm B45
2 3 3d 5d
3 1 1 0
4 1 1 2
5 1 0 0
Number of patients with carboplatin dose reductions
1 dose reduction 1 1 2
2 dose reductions 2 0 2
aTwo patients went on to receive five further cycles of carboplatin alone.
bOne patient went on to receive two further cycles of carboplatin alone.
cOne patient went on to receive two further cycles of carboplatin alone.
dOne further patient had a delay ofo7 days.
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following a carboplatin hypersensitivity reaction, more patients
stopped treatment due to hypersensitivity reactions to carboplatin
in Arm B than in Arm A (4 vs 1). (See Table 3 for other adverse
events).
Dose intensity. There was no significant difference in total dose of
carboplatin between the arms (A: median 32.67 AUC (inter-
quartile range 17.03–36.05); B90: 18.04 (9.75–28.57); B45: 23.05
(11.97–35.81) (P¼ 0.430)). There was a statistically significant
difference in carboplatin relative dose intensity between all three
arms (A 95.85 (89.43–100); B90: 79.17 (69.27–87.79); B45: 90.07
(85.39–96.55; P¼ 0.031) but not between A and B45 (P¼ 0.378),
indicating that the difference was due to the difference between
B90 and A.
Efficacy. By combined GCIG (CA125) criteria, 9 out of 14 in Arm
A vs 3 out of 15 in the combination arm responded (P¼ 0.025).
Twenty-five patients were evaluable by RECIST criteria, 7 out of 13
patients had a response (1 CR, 6 PR), in Arm A and 1 out of 12 in
the combination arm. (P¼ 0.072) (Table 4). The median response
duration for carboplatin alone was 9.3 months (range 1.9 to419.5
months) compared with 2.6 months (range 1.9-7.3 months) for
B45. The median PFS was 6.9 months (95% CI 4.3–9.4) for
carboplatin alone, 1.9 months for B90 (0–9.4) and 6 months
for B45 (95% CI 1–11) (Figure 1). Only three patients had
methylated MLH1), two in A (achieving CR and PR) and one in
B90 (stable disease).
Study closure. A pre-planned formal assessment of tumour
responses was performed after the first 11 patients had been
recruited into B45. The one RECIST responder in fact only
received one cycle of combination treatment followed by five cycles
of carboplatin and two others had short-lived CA125 responses
only and progressed before the end of treatment. In addition, the
deliverability of B45 was difficult due to hypersensitivity and
neutropenia. No patients in this arm completed six cycles as per
protocol, indicating that treating sufficient patients in B45 to
evaluate the study was very unlikely to be achievable. As a result,
the decision was made to terminate the study.
Pharmacokinetics and pharmacodynamic end points. Pharma-
cokinetic data were available for 11 out of 15 patients in Arm B.
The mean concentration of decitabine 1 h post infusion was
125.69 ngml 1 (s 58.46; range 84.18–192.55) for B90 and
53.17 ngml 1 (s 16.47; range 24.06–72.91) for B45.
Global 5-methyl-20-deoxycytidine levels were measured in DNA
from peripheral blood cells in all 29 patients. Decitabine resulted in
a decrease in global levels of methylation, becoming maximal 10
days after decitabine and returning to baseline by day 22 (Figure 2).
This was in contrast to the stable levels of global methylation
observed with carboplatin alone. There was a statistically
significant correlation between the concentration of decitabine
1 h after the start of the infusion and minimum global methylation
(Spearman correlation coefficient  0.65; P¼ 0.037, 90% CI
 0.90 to  0.20) and the area above the methylation curve
(Spearman correlation coefficient 0.85; P¼ 0.002, 90% CI  0.56
to 0.96).
DISCUSSION
Data from our group and others have indicated that DNA
methylation-induced gene silencing may have a role both in the
Table 3. Adverse events by treatment arm including grade 2 or above
toxicity where grade 2 or above toxicity occurred in at least 5% of
patients and grade 1 or above hypersensitivity reactions
Adverse event Grade Arm A Arm B90 Arm B45
% (no of patients)
Haemoglobin 2 30.8 (4) 0 45.5 (5)
4 7.7 (1) 0 9.1 (1)
Infection with unknown ANC 2 7.1 (1) 0 18.2 (2)
Leucopenia 2 30.8 (4) 25 (1) 45.5 (5)
3 0 75 (3) 9.1 (1)
Lymphopenia 2 7.7 (1) 25 (1) 9.1 (1)
3 7.7 (1) 25 (1) 9.1 (1)
Neutropenia 2 46.2 (6) 0 27.3 (3)
3 15.4 (2) 25 (1) 36.4 (4)
4 0 75 (3) 9.1 (1)
Thrombocytopenia 2 7.7 (1) 0 0
3 0 0 9.1 (1)
4 15.4 (2) 0 9.1 (1)
Nausea 2 14.3 (2) 25 (1) 27.3 (3)
Vomiting 2 14.3 (2) 0 18.2 (2)
Pain 2 0 0 27.3 (3)
Hypersensitivity 1 0 25 (1) 18.2 (2)
2 7.1 (1) 25 (1) 27.3 (3)
3 14.3 (2) 25 (1) 18.2 (2)
Constipation 2 0 0 18.2 (2)
Dyspnoea 3 0 0 9.1 (1)
4 0 25 (1) 0
Fatigue 2 35.7 (5) 25 (1) 63.6 (7)
Hypoalbuminaemia 2 7.7 (1) 25 (1) 27.3 (3)
GGT 2 7.7 (1) 0 9.1 (1)
3 0 0 18.2 (2)
4 7.7 (1) 0 0
AST 2 15.4 (2) 0 9.1 (1)
Hypophosphataemia 2 23.1 (3) 0 30 (3)
3 0 0 10 (1)
Hyperglycaemia 2 15.4 (2) 0 27.3 (3)
3 7.7 (1) 0 0
Abbreviations: ANC¼ absolute neutrophil count; AST¼ aspartate transaminase;
GGT¼gamma glutamyl transferase.
Table 4. Best response by combined RECIST and/or GCIG CA125 criteria
and by RECIST alone
Arm A
Arm
B90
Arm
B45
Total
% (no. of patients)
Complete response 7.1 (1) 0 (0) 0 (0) 3.4 (1)
Partial response 57.1 (8) 0 (0) 27.3 (3) 37.9 (11)
Stable disease 28.6 (4) 50 (2) 45.5 (5) 41.4 (12)
Progressive disease 0 50 (2) 18.2 (2) 10.3 (3)
Unevaluable 7.1 (1) 0 (0) 9.1 (1) 6.9 (2)
Total 100 (14) 100 (4) 100 (11) 100 (29)
Responses by RECIST alone 1 CR 0 CR 0 CR 1 CR
5 PR 0 PR 1 PR 6 PR
5 SD 1 SD 5 SD 11 SD
0 PD 2 PD 2 PD 4 PD
2 NE 0 NE 1 NE 2 NE
Abbreviations: CR¼ complete response; GCIG¼Gynecological Cancer Intergroup;
NE¼not evaluable; PD¼progressive disease; PR¼partial response; RECIST¼Response
Evaluation Criteria In Solid Tumors; SD¼ stable disease.
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development of resistance to cytotoxic chemotherapeutic agents
and in the deterioration of drug sensitivity, according to the genes
involved (Glasspool et al, 2006; Chang et al, 2010). Unlike genetic
modification, epigenetic modifications require active maintenance
and hence may be amenable to pharmacological intervention and
reversal. Decitabine sequesters DNA methyltransferases, leading to
demethylation of DNA following DNA replication. Decitabine has
activity in MDS and AML, but its single agent activity in solid
tumours has been disappointing (Graham et al, 2009). However,
cell line and xenograft studies showed that demethylation of drug-
resistant tumours can lead to chemosensitisation (Plumb et al,
2000), and decitabine may be most effectively used in solid
tumours in combination with cytotoxics, such as carboplatin.
Older studies investigating the combination of cytotoxic agents and
decitabine used maximally tolerated doses and schedules, which
would not have allowed any demethylation, gene re-expression or
drug sensitisation to occur before delivery of the cytotoxic agent.
At higher doses, it has direct cytotoxic activity as a result of
incorporation into DNA. However, its effects on demethylation
and gene expression may be achieved at lower doses than the
maximally tolerated dose (Kantarjian et al, 2007). In the present
study, we used a schedule and dose of decitabine shown to
induce equivalent demethylation in surrogate tissues at the
time of carboplatin administration as that which re-induced
platinum sensitivity in xenografts models (Plumb et al, 2000;
Appleton et al, 2007).
The study included patients who had relapsed between 6 and 12
months following platinum therapy; we excluded patients with
platinum-free interval of o6 months as our policy for those is to
treat with non-platinum agents. Although randomised studies have
indicated that carboplatin in combination with paclitaxel or
gemcitabine improves overall or PFS compared with single agent
carboplatin in relapsed patients withX6-month platinum-free
interval (Parmar et al, 2003; Pfisterer et al, 2006), combination
therapy is not appropriate for all patients, and all the investigators
in the study considered that single agent carboplatin was still an
acceptable control arm in selected patients in this 6–12 month
subgroup.
In our phase I study, the maximal mean decrease in levels of
5-methyl-2’-deoxycytidine in peripheral mononuclear cell DNA was
33% in patients receiving 45mgm 2 decitabine vs 35% in patients
receiving 90mgm 2, indicating that 45mgm 2 induced only
marginally less demethylation (Appleton et al, 2007). In this study,
both 90 and 45mgm 2 of decitabine induced a decrease in global
methylation comparable to the phase I. In xenograft models, doses
of decitabine that cause sensitisation to carboplatin of xenografts in
mice induce a 27% mean reduction in 5-methyl-20-deoxycytidine
levels in PBMC (Plumb et al, 2000). Thus, the reduction in
5-methyl-20-deoxycytidine levels in PBMC seen in patients in this
study was equivalent or greater to that observed in murine PBMC,
with doses of decitabine that, in mice, produce concomitant
demethylation, re-expression of epigenetically silenced genes and
chemosensitisation in drug-resistant xenografts.
In the population included in this study, we found that the
combination was not feasible at a dose of 90mgm 2 of decitabine
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due to neutropenia. Hypersensitivity reactions also reduced the
deliverability of the combination. This differed from the findings of
the phase I study, but in this, dose-limiting toxicity was only assessed
in the first cycle and few patients received more than two cycles, so
the cumulative toxicity was not apparent. In the phase I study, the
majority of patients had not had previous exposure to carboplatin
and no hypersensitivity reactions occurred in these patients, so again
this toxicity was not apparent until the phase II study.
Two other phase I studies have investigated the combination of
a demethylating agent and carboplatin in ovarian cancer patients.
Both included patients with disease relapsing within 6 months of
their last carboplatin and both used 5-day schedules for the
demethylating agent and carboplatin of AUC 4 or 5 on a 28-day
schedule (Fang et al, 2010; Fu et al, 2011). Despite the relatively
low dose intensity of carboplatin and more platinum-resistant
populations, both studies saw responses (11% and 13.8%),
although in the study by Fu et al (2011), the majority of patients
with platinum-resistant disease had received other therapy before
study entry, and actual platinum-free intervals ranged from 6 to 31
months. Activity of the combination has been confirmed in a
subsequent non-randomised phase II trial performed by Matei et al
(2012), with a RR 35% and median PFS of 10.2 months, which is
certainly higher than would be expected in a platinum-resistant
population treated with carboplatin alone. Interestingly, despite the
lower dose of carboplatin (AUC 5 q 28days), Matei et al (2012) had
to give peg-filgastrim to avoid prolonged neutropenia, and they
also saw a high rate of hypersensitivity reactions (35%).
The reason for our differing results is not clear. The low RR in
our study was not explained by significant differences in
carboplatin dose intensity (between Arm A and B45). In these
other studies, the responses often occurred after several cycles,
suggesting that more prolonged treatment with a demethylating
agent than we achieved may be required. It is also possible that the
5-day schedule induced more prolonged demethylation during
each cycle, which was more effective in reversing resistance.
Alternatively, the inclusion of patients witho6 months PFS in
these positive studies may have selected a group of patients more
responsive to demethylating agents than the 6–12 month group.
Indeed, it is possible that in our population decitabine caused
demethylation of other genes, which resulted in a reduction rather
than an increase in platinum sensitivity in some cases. An example
might be BRCA1 where methylation is associated with response to
platinum-based chemotherapy at presentation (Teodoridis et al,
2005). Hence, demethylation could have resulted in re-expression
of BRCA1 and a decrease in sensitivity to carboplatin in the 6–12
month group, where it is conceivable that demethylation of BRCA
may be less significant in theo6 month group when other
mechanisms of platinum resistance may predominate.
Our study was designed to allow inclusion of sufficient patients
with methylation of MLH1 CGI to allow separate analysis of this
group; however, a lower than anticipated rate of MLH1 CGI
methylation and early closure of the study meant that too few
patients were included for this to be feasible. Interestingly, Matei
et al (2012) found that demethylation of MLH1, RASSF1a and
HOXA10/11 correlated positively with PFS (Po0.05) supporting
our original hypothesis.
The high incidence of hypersensitivity reactions contributed to
the difficulty in delivering the combination therapy. The reason for
this increase is unknown but is potentially the result of demethyla-
tion and re-expression of immune-modifying genes. Interleukin
(IL)-4 and interferon (IFN)-g are major cytokines that affect the
differentiation of naive CD4þ T lymphocytes into the Th1 and Th2
lineage, which control IgE production, the mediator of hypersensi-
tive reactions. The promoter regions are largely methylated in both
the IL-4 and IFN-g genes in T-lymphocytes, and it has been
suggested that demethylation correlates with increased expression
and hence hypersensitivity (Kwon et al, 2008).
In conclusion, decitabine is difficult to deliver in combination
with carboplatin AUC 6 on a 28-day schedule; moreover, in this
patient group and using this schedule it definitely does not increase
and may decrease the RR to carboplatin. Other demethylating
agents are in development; these may be easier to deliver with less
myelosuppression, and other schedules, for example, a 5-day
schedule, may induce more marked and persistent demethylation.
In addition, a greater understanding of the significance of
methylation of specific genes is critically required in order to
identify a population with drug-resistant ovarian cancer who may
benefit most from this approach.
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